JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

JNJ

167.25

+1.51%↑

NVS

115.07

+1.29%↑

ABT

127.38

+0.96%↑

TMO

462.78

-1.04%↓

ISRG

483.28

+0.46%↑

Kodu・Aktsiate loetelu・AbCellera Biologics Inc

AbCellera Biologics Inc

Suletud

SektorTervishoid

4.22 -5.17

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

4.19

Max

4.26

Põhinäitajad
By Trading Economics
Sissetulek	-11M -46M
Müük	-815K 4.2M
Kasumimarginaal	-1,077.237
Töötajad	596
EBITDA	16M -40M

Soovitused
By TipRanks
Soovitused	Tugev "osta" hinnang
12 kuu keskmine prognoos	+135.85% upside

Dividendid
By Dow Jones
Järgmine tulemuste avaldamine	7. aug 2025

Turustatistika
By TradingEconomics
Turukapital	854M 1.5B
Eelmine avamishind	9.39
Eelmine sulgemishind	4.22

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

1.99 / 2.635 Toetus ja vastupanu

AbCellera Biologics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

1. aug 2025, 17:41 UTC

Tulu

Suurimad hinnamuutused turgudel

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

1. aug 2025, 17:40 UTC

Tulu

Suurimad hinnamuutused turgudel

Colgate Plans More Price Increases to Offset Slower Sales, Higher Costs -- Update

2. aug 2025, 15:47 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- Update

2. aug 2025, 13:29 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 13:10 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 12:59 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 12:53 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2. aug 2025, 12:52 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire's Quarterly Earnings Drop on Insurance Results, Currency Moves -- WSJ

2. aug 2025, 12:44 UTC

Tulu

Omandamised, ülevõtmised, äriostud

Berkshire Operating Profits Fall 4% in 2nd Quarter. Company Takes Write-Down of Kraft Equity Stake. -- Barrons.com

2. aug 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1. aug 2025, 22:31 UTC

Tulu

MicroStrategy Stock Drops 9%. New Equity Guidelines Could Be the Reason. -- Barrons.com

1. aug 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

1. aug 2025, 20:28 UTC

Omandamised, ülevõtmised, äriostud

EOG Resources Completes $5.6B Purchase of Encino Acquisition Partners

1. aug 2025, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

1. aug 2025, 20:08 UTC

Market Talk

U.S. Stocks Tumble as U.S. Jobs Market Weakens, New Tariffs Hit -- Market Talk

1. aug 2025, 19:54 UTC

Market Talk

Mexico Manufacturing Indexes Mixed in July -- Market Talk

1. aug 2025, 19:54 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. aug 2025, 19:42 UTC

Market Talk

Treasury Yields Start Month With Jobs-Driven Decline -- Market Talk

1. aug 2025, 19:40 UTC

Market Talk

Global Energy Roundup: Market Talk

1. aug 2025, 19:40 UTC

Market Talk

U.S. Natural Gas Futures Hold Above Key Support -- Market Talk

1. aug 2025, 19:19 UTC

Market Talk

Livestock Brings Positive Momentum Into August -- Market Talk

1. aug 2025, 19:13 UTC

Market Talk

Crude Falls on Soft U.S. Jobs Data, OPEC+ Output Expectations -- Market Talk

1. aug 2025, 19:07 UTC

Omandamised, ülevõtmised, äriostud

Danone to Explore Buying Lifeway Foods. The Third Time Could Be Different. -- Barrons.com

1. aug 2025, 18:38 UTC

Market Talk

Grains Shrug Off Lower Dollar -- Market Talk

1. aug 2025, 18:38 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

1. aug 2025, 17:53 UTC

Omandamised, ülevõtmised, äriostud

Correction to M&A Is Back. These Stocks Could Be Targets. -- Barrons.com

1. aug 2025, 17:52 UTC

Market Talk

Gold Finishes Higher Amid Weak July Hiring and Tariffs -- Market Talk

1. aug 2025, 17:38 UTC

Market Talk

U.S. Oil Rig Count Down By 5 to 410 -- Market Talk

1. aug 2025, 17:06 UTC

Tulu

Earnings Season Is Going Really Well. Don't Overthink It. -- Barrons.com

1. aug 2025, 16:55 UTC

Tulu

Big Takeaways From Big Tech Earnings -- Barrons.com

Võrdlus sarnastega

Hinnamuutus

AbCellera Biologics Inc Prognoos

Hinnasiht

By TipRanks

135.85% tõus

12 kuu keskmine prognoos

Keskmine 10 USD 135.85%

Kõrge 17 USD

Madal 5 USD

Põhineb 5 Wall Streeti analüütiku instrumendi AbCellera Biologics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Tugev "osta" hinnang

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi AbCellera Biologics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

1.99 / 2.635Toetus ja vastupanu

Recent bearish events outweigh bullish events.

Bearish events outweigh bullish events.

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

Ettevõttest AbCellera Biologics Inc

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.